[HTML][HTML] Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled …

…, M Voysey, C Green, AD Douglas, AVS Hill, T Lambe… - The Lancet, 2020 - thelancet.com
Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …

[HTML][HTML] Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind …

…, MEE Watson, AD Douglas, AVS Hill, T Lambe… - The Lancet, 2020 - thelancet.com
Background Older adults (aged ≥70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …

[PDF][PDF] Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum

…, T Dong, AJ Pollard, JC Knight, D Crook, T Lambe… - Cell, 2021 - cell.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive
change, with variants conferring advantage rapidly becoming dominant lineages, eg, B.…

[HTML][HTML] Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South …

…, CJ Williams, AD Douglas, AVS Hill, T Lambe… - The Lancet, 2021 - thelancet.com
Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …

[HTML][HTML] Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

…, KM Thomas, J Vekemans, TL Villafana, T Lambe… - Nature medicine, 2021 - nature.com
The global supply of COVID-19 vaccines remains limited. An understanding of the immune
response that is predictive of protection could facilitate rapid licensure of new vaccines. Data …

[PDF][PDF] SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses

…, H Webster, D Crook, AJ Pollard, T Lambe… - Cell, 2022 - cell.com
On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529
was announced, containing far more mutations in Spike (S) than previously reported …

[HTML][HTML] Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant

…, E Horne, SH Hwa, A Jose, T Lambe… - … England Journal of …, 2021 - Mass Medical Soc
Background Assessment of the safety and efficacy of vaccines against the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …

[HTML][HTML] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a …

…, T White, CJ Williams, AD Douglas, AVS Hill, T Lambe… - The Lancet, 2021 - thelancet.com
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …

[PDF][PDF] Antibody escape of SARS-CoV-2 Omicron BA. 4 and BA. 5 from vaccine and BA. 1 serum

…, E Barnes, SJ Dunachie, D Crook, AJ Pollard, T Lambe… - Cell, 2022 - cell.com
The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread
rapidly to become globally dominant and has split into a number of sublineages. BA.1 …

[HTML][HTML] Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV …

…, A Hicks, AA van der Klaauw, J Kwok, T Lambe… - The Lancet, 2021 - thelancet.com
Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …